RBR-8xdc8yz
Not yet recruiting
Phase 2
Randomized clinical trial to evaluate the safety and pharmacodynamics of the PARP inhibitor Olaparib in sepsis - PARP Poly [ADP-ribose] polymerase
Escola Paulista de Medicina, Universidade Federal de São Paulo0 sitesDecember 30, 2022
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Escola Paulista de Medicina, Universidade Federal de São Paulo
- Status
- Not yet recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Male patients diagnosed with septic shock for less than 24 hours; signing of free and informed consent form
Exclusion Criteria
- •Female patients (women) because women's hormones can alter the effects of olaparib; patients unable to use medication by mouth or by tube; patients with AIDS; patients using immunosuppressive therapy, that is, which compromises the body's defenses; patients using corticosteroids; patients with cancer or undergoing chemotherapy; chemotherapy performed up to 30 days; patients who had cardiac arrest; patients with recent acute infarction or problems with the coronary artery, the artery that supplies the heart; liver disease, such as liver cirrhosis; very severe patients, with the prospect of death within 24 hours; palliative or end\-of\-life care; patients using treatments that may have their effects altered or alter the effects of olaparib (examples: itraconazole, fluconazole, verapamil, rifampicin, phenytoin, carbamazepine, phenobarbital and modafinil; Saint John's herb)
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Not Applicable
Evaluation of the safety and effectiveness of esmolol and metoprolol for heart rate reduction during heart CT examinatioHeart rate control of patients referred to coronary computed tomography angiography (CCTA) due to suspected coronary artery disease are to investigated with esmolol and metoprolol. Acquiring diagnostic image quality with CCTA requires relative low and stable heart rate of the patients during examination. Thus, heart rate control with beta-blocker medication (esmolol, metoprolol) is recommended. However no current guideline is available regarding esmolol administration during CCTA.MedDRA version: 14.1Level: PTClassification code 10011078Term: Coronary artery diseaseSystem Organ Class: 10007541 - Cardiac disordersTherapeutic area: Diseases [C] - Cardiovascular Diseases [C14]EUCTR2013-000048-24-HUHear Center of Semmelweis University
Recruiting
Not Applicable
Randomized-controlled trial to assess the safety and efficacy of preoperative chemotherapy in patients with locally advanced colon cancerNeoplasmsKCT0003077Kyungpook National University Medical Center708
Recruiting
Not Applicable
A randomized clinical trial to evaluate the safety and effectiveness of the full-veneer crown fabricated with a 3D printed resin material for definitive prosthesisCodes for special purposesKCT0006081Yonsei University Health System, Dental Hospital60
Active, not recruiting
Not Applicable
Randomized trial to assess efficacy and safety of an add-on treatment with zonisamide in adults with focal epileptic seizures with or without secondary generalizatioPartial epileptic seizures with or without secondary generalisationMedDRA version: 7.1Level: PTClassification code 10040703EUCTR2005-000260-57-DEEisai GmbH
Not yet recruiting
Not Applicable
ength of nasogastric tube(Ryles tube) will be increased by 10 cm during insertion in patients with acute poisoning for evacuation of poison.Health Condition 1: T600- Toxic effect of organophosphate and carbamate insecticidesHealth Condition 2: T600- Toxic effect of organophosphate and carbamate insecticidesCTRI/2019/05/018914PGIMER Chandigarh